Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ZI-MA4-1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zelluna Finalizes Manufacturing for TCR-NK Therapy ZI-MA4-1 Clinical Entry
Details : ZI-MA4-1 is a TCR-NK off-the-shelf cell therapy developed by Zelluna Immunotherapy AS targeting solid tumors, specifically those expressing MAGE-A4.
Product Name : ZI-MA4-1
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 22, 2025
Lead Product(s) : ZI-MA4-1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Lion TCR
Deal Size : Undisclosed
Deal Type : Collaboration
Zelluna Collaborates with Lion TCR to Develop TCR-NK Cell Therapies to Treat Virally Induced Cancers
Details : The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Lion TCR
Deal Size : Undisclosed
Deal Type : Collaboration